N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised Dosing, Is Associated with Safety and Activity By Ogkologos - January 23, 2026 317 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the I-PREDICT study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Study Says Exercise Combats Side Effects of Chemo and Other Meds... July 7, 2021 News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and... July 11, 2020 Researchers Create Modified Antibodies to Target RAS and p53 in Cancer April 2, 2021 A Short-Course of Induction Chemotherapy Followed by Chemoradiotherapy Significantly Improves Survival... October 31, 2024 Load more HOT NEWS Researchers Discover Genetic Marker That Increases Risk Of Premenopausal Breast Cancer Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer Why the voices of people affected by cancer are critical to... Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer
